	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the	1
		abstract	
		(b) Provide in the abstract an informative and balanced summary of what	4
		was done and what was found: why the study was conducted, the design, the	
		results, the limitations, and the relevance of the findings.	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being	6
		reported	
Objectives	3	(a) State specific objectives, including any prespecified hypotheses	7
		(b) Ensure that the level of organization is clear for each objective and	7
		hypothesis	
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	(a) Describe the setting, locations, and relevant dates, including periods of	8
		recruitment, exposure, follow-up, and data collection	
		(b) If applicable, include information at each level of organization.	-
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of	8
		participants. Describe methods of follow-up	
		(b) For matched studies, give matching criteria and number of exposed and	-
		unexposed	
Variables	7	(a) Clearly define all outcomes, exposures, predictors, potential confounders,	8
		and effect modifiers. Give diagnostic criteria, if applicable	
		(b) Describe the level of organization at which each variable was measured	8-10
		(c) For hypothesis-driven studies, the putative causal structure among	-
		variables should be described	
Data sources/	8*	(a) For each variable of interest, give sources of data and details of methods	8-10
measurement		of assessment (measurement). Describe comparability of assessment	
		methods if there is more than one group	
		(b) If a questionnaire was used to collect data, describe its development,	

Item No.	Recommendation	Page No
110	validation, and administration	9
	(c) Describe whether or not individuals involved in data collection were	
	blinded, when applicable	-
	(d) Describe any efforts to assess the accuracy of the data (including	
	methods used for "data cleaning" in primary research, or methods used for	-
	validating secondary data)	
9	Describe any efforts to address potential sources of bias	17-18
10	(a) Describe how the study size was arrived at for each relevant level of	8 &11
	organization	
	(b) Describe how nonindependence of measurements was incorporated into	-
	sample-size considerations, if applicable	
	(c) If a formal sample-size calculation was used, describe the parameters,	-
	assumptions, and methods that were used, including a justification for the	
	effect size selected	
11	Explain how quantitative variables were handled in the analyses. If	7-8
	applicable, describe which groupings were chosen and why	
12	(a) Describe all statistical methods, including those used to control for	9-10 &
	confounding	17-18
	(b) Describe any methods used to examine subgroups and interactions	-
	(c) Explain how missing data were addressed	10
	(d) If applicable, describe the analytical approach to loss to follow-up,	9-10
	matching, complex sampling, and multiplicity of analyses	
	(e) Describe any methods used to assess the robustness of the analyses	-
13	(a) Report numbers of individuals at each stage of study—eg numbers	11
	potentially eligible, examined for eligibility, confirmed eligible, included in	
	the study, completing follow-up, and analysed	
	(b) Give reasons for non-participation at each stage	-
	(c) Consider use of a flow diagram	Supp2
14	(a) Give characteristics of study participants (eg demographic, clinical,	11
	11 12 13	validation, and administration (c) Describe whether or not individuals involved in data collection were blinded, when applicable (d) Describe any efforts to assess the accuracy of the data (including methods used for "data cleaning" in primary research, or methods used for validating secondary data) 9 Describe any efforts to address potential sources of bias 10 (a) Describe how the study size was arrived at for each relevant level of organization (b) Describe how nonindependence of measurements was incorporated into sample-size considerations, if applicable (c) If a formal sample-size calculation was used, describe the parameters, assumptions, and methods that were used, including a justification for the effect size selected 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why 12 (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, describe the analytical approach to loss to follow-up, matching, complex sampling, and multiplicity of analyses (e) Describe any methods used to assess the robustness of the analyses 13 (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram

	Item No	Recommendation	Page No
	210	social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of	11-15
		interest	
		(c) Summarise follow-up time (eg, average and total amount)	15
Outcome data	15	(a) Report outcomes as appropriate for the study design and summarize at all	14-15
		relevant levels of organization	
		(b) For proportions and rates, report the numerator and denominator	15
		(c) For continuous outcomes, report the number of observations and a	-
		measure of variability	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	11-15 &
		estimates and their precision (eg, 95% confidence interval). Make clear	17-18
		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	-
		(c) If relevant, consider translating estimates of relative risk into absolute	-
		risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and	15
		sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	16-17
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias	17-18
		or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	16-18
		limitations, multiplicity of analyses, results from similar studies, and other	
		relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	17-18
Other information			
Transparency	22	(a) Funding—Give the source of funding and the role of the funders for the	1
		present study and, if applicable, for the original study on which the present	
		article is based	
		(b) Conflicts of interest—Describe any conflicts of interest, or lack thereof,	1

Item No	Recommendation	Page No
	for each author	
	(c) Describe the authors' roles—Provision of an author's declaration of	1
	transparency is recommended	
	(d) Ethical approval—Include information on ethical approval for use of	1
	animal and human subjects	
	(e) Quality standards—Describe any quality standards used in the conduct of	1
	the research	

Supporting Information 1: STROBE Vet-Statement—Checklist (20-21)